摘要
目的探讨莫沙必利对乙型肝炎肝硬化代偿期肠道微生态的影响。方法选择2016年1月~2018年6月在我院诊断治疗的乙型肝炎肝硬化患者60例为研究对象,按照入院单双号分为观察组与对照组各30例。对照组采用恩替卡韦分散片口服治疗,观察组在此基础上加用莫沙必利片治疗。比较治疗前后肠道菌群变化、血清内毒素水平以及腹胀、恶心呕吐、食欲不振发生率。结果治疗后观察组肠道菌群中肠球菌(12.2±3.0)lgn/g,大肠杆菌(11.5±3.3)lgn/g,显著低于治疗前及对照组治疗后,差异有统计学意义(P<0.05);治疗后观察组乳酸杆菌(27.2±4.3)lgn/g,双歧杆菌(29.2±5.1)lgn/g,显著高于治疗前及对照组治疗后,差异有统计学意义(P<0.05)。治疗后观察组血清内毒素水平(28.8±5.4)Eu/mL,显著低于治疗前以及对照组治疗后,差异有统计学意义(P<0.05)。观察组治疗后肠道症状腹胀、食欲不振、恶心呕吐的发生率显著下降,与治疗前比较差异有统计学意义(P<0.05);治疗后,观察组腹部症状发生率显著低于对照组治疗后,差异有统计学意义(P<0.05)。结论乙型肝炎肝硬化代偿期患者存在肠道菌群失调,莫沙必利能够有效调节患者肠道微生态,改善患者症状。
Objective To investigate the effect of mosapride on intestinal micro-ecology in the compensatory period of hepatitis B cirrhosis. Methods 60 patients with hepatitis B cirrhosis diagnosed and treated in our hospital from January 2016 to May 2018 were selected as subjects. According to the admission single and double numbers, they were divided into observation group(n=30) and control group(n=30). The control group was treated with entecavir dispersible tablets orally, and the observation group was treated with mosapride tablets based on the above treatment. The intestinal flora changes, serum endotoxin levels and bloating, nausea and vomiting, and loss of appetite before and after treatment were compared. Results After treatment, the enterococci(12.2±3.0) lgn/g and E. coli(11.5±3.3) lgn/g in the intestinal flora of the observation group were significantly lower than those before treatment and those of the control group after treatment. The difference was statistically significant(P<0.05). After treatment, the lactobacillus(27.2±4.3) lgn/g, and bifidobacteria(29.2±5.1) lgn/g in the observation group were significantly higher than those before treatment and those in the control group after treatment, and the difference was statistically significant(P<0.05). After treatment, the serum endotoxin level in the observation group was(28.8±5.4)Eu/mL, which was significantly lower than that before treatment and that of the control group after treatment(P<0.05). After the treatment, the incidence of intestinal bloating, loss of appetite, nausea and vomiting decreased significantly in the observation group, which was significantly different from that before treatment(P<0.05). After treatment, the incidence of abdominal symptoms in the observation group was significantly lower than that in the control group, and the difference was statistically significant(P<0.05). Conclusion Patients with hepatitis B cirrhosis compensated patients have intestinal flora imbalance. Mosapride can effectively regulate intestinal micro-ecology and improve patients' symptoms.
作者
丁青
陈冻伢
DING Qing;CHEN Dongya(Department of Gastroenterology,Hangzhou Red Cross Hospital,Hangzhou 310003,China)
出处
《中国现代医生》
2019年第23期44-47,共4页
China Modern Doctor
基金
浙江省医药卫生科研面上项目(2018KY602)
关键词
莫沙必利
乙型肝炎
肝硬化
代偿期
肠道微生态
Mosapride
Hepatitis B
Liver cirrhosis
Compensation period
Intestinal microecology
